Literature DB >> 21376137

Heparanase: a universal immunotherapeutic target in human cancers.

Ya-Fei Zhang1, Xu-Dong Tang, Jin-Hua Gao, Dian-Chun Fang, Shi-Ming Yang.   

Abstract

Heparanase has been identified as a particularly important player in metastasis, and its expression directly correlates with the metastatic spread of various tumors. Ideal targets for immunotherapy are gene products that are silenced in normal tissues but overexpressed in cancer, and that are directly involved in tumor cell survival and progression. Metastasis is the culmination of neoplastic progression. The importance of the role of heparanase in metastasis implies that immune escape by downregulation of heparanase expression could reduce the mortality of the cancer. These characteristics of heparanase make it an attractive universal target for cancer immunotherapy. Here, we review current knowledge about heparanase and its involvement in tumor metastasis, with an emphasis on recent results from heparanase-targeted cancer immunotherapy studies.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21376137     DOI: 10.1016/j.drudis.2011.02.015

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  10 in total

1.  Heparanase and cancer progression: New directions, new promises.

Authors:  Gil Arvatz; Marina Weissmann; Neta Ilan; Israel Vlodavsky
Journal:  Hum Vaccin Immunother       Date:  2016-04-07       Impact factor: 3.452

Review 2.  Heparanase: From basic research to therapeutic applications in cancer and inflammation.

Authors:  Israel Vlodavsky; Preeti Singh; Ilanit Boyango; Lilach Gutter-Kapon; Michael Elkin; Ralph D Sanderson; Neta Ilan
Journal:  Drug Resist Updat       Date:  2016-10-06       Impact factor: 18.500

Review 3.  Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.

Authors:  Ralph D Sanderson; Michael Elkin; Alan C Rapraeger; Neta Ilan; Israel Vlodavsky
Journal:  FEBS J       Date:  2016-11-16       Impact factor: 5.542

4.  PI-88 inhibits postoperative recurrence of hepatocellular carcinoma via disrupting the surge of heparanase after liver resection.

Authors:  Bo-Yi Liao; Zheng Wang; Jie Hu; Wei-Feng Liu; Zao-Zhuo Shen; Xin Zhang; Lei Yu; Jia Fan; Jian Zhou
Journal:  Tumour Biol       Date:  2015-09-28

5.  In vitro and ex vivo evaluation of a multi-epitope heparinase vaccine for various malignancies.

Authors:  Xu-Dong Tang; Shu-Liang Guo; Guo-Zhen Wang; Ning Li; Yu-Yun Wu; Dian-Chun Fang; Ya-Han Fan; Shi-Ming Yang
Journal:  Cancer Sci       Date:  2013-11-29       Impact factor: 6.716

6.  Inhibition of Heparanase Expression Results in Suppression of Invasion, Migration and Adhesion Abilities of Bladder Cancer Cells.

Authors:  Yoshihiro Tatsumi; Makito Miyake; Keiji Shimada; Tomomi Fujii; Shunta Hori; Yosuke Morizawa; Yasushi Nakai; Satoshi Anai; Nobumichi Tanaka; Noboru Konishi; Kiyohide Fujimoto
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

Review 7.  Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression.

Authors:  Arvindhan Nagarajan; Parmanand Malvi; Narendra Wajapeyee
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-24       Impact factor: 5.555

8.  Upregulation of Endothelin-1/Endothelin A Receptor Expression Correlates with Heparanase Expression in Ovarian Carcinoma.

Authors:  Nungki Anggorowati; Ahmad Ghozali; Irianiwati Widodo; Dwi Cahyani Ratna Sari; Muhammad Mansyur Romi; Nur Arfian
Journal:  Iran J Med Sci       Date:  2018-05

9.  Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors.

Authors:  Edward Hammond; Nicole M Haynes; Carleen Cullinane; Todd V Brennan; Darryn Bampton; Paul Handley; Tomislav Karoli; Fleur Lanksheer; Liwen Lin; Yiping Yang; Keith Dredge
Journal:  J Immunother Cancer       Date:  2018-06-14       Impact factor: 13.751

10.  Protease, Growth Factor, and Heparanase-Mediated Syndecan-1 Shedding Leads to Enhanced HSV-1 Egress.

Authors:  Ghadah A Karasneh; Divya Kapoor; Navya Bellamkonda; Chandrashekhar D Patil; Deepak Shukla
Journal:  Viruses       Date:  2021-09-01       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.